CMPS
COMPASS Pathways plc NASDAQ Listed Sep 18, 2020$12.53
+4.94%
vs $11.94
Mkt Cap $1.2B
52w Low $2.35
86.0% of range
52w High $14.19
50d MA $10.11
200d MA $7.19
P/E (TTM)
—
EV/EBITDA
—
P/B
—
Debt/Equity
-0.4x
ROE
544.7%
P/FCF
-7.5x
RSI (14)
46.60
ATR (14)
$0.98
Beta
2.02
50d MA
$10.11
200d MA
$7.19
Avg Volume
3.9M
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
33 Broadwick Street · London, X0 W1F 0DQ · GB
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 13, 2026 | BMO | -0.45 | -0.30 | +33.3% | 9.37 | +5.1% | +17.0% | -3.1% | -2.4% | +1.8% | -4.6% | — |
| Mar 24, 2026 | BMO | -0.41 | -0.59 | -43.9% | 5.22 | +1.7% | +7.7% | +0.4% | -4.8% | -2.4% | +5.5% | — |
| Nov 4, 2025 | BMO | -0.40 | -0.38 | +5.0% | 6.63 | -1.4% | -17.2% | +1.8% | -2.5% | +5.3% | -0.7% | — |
| Jul 31, 2025 | BMO | -0.37 | -0.38 | -2.7% | 4.35 | -1.8% | -0.2% | +6.0% | -2.6% | -2.7% | -1.1% | — |
| May 8, 2025 | BMO | -0.47 | -0.44 | +6.4% | 3.76 | -1.6% | +0.8% | +3.2% | -0.3% | -1.0% | +2.3% | — |
| Feb 27, 2025 | BMO | -0.62 | -0.63 | -1.6% | 3.92 | -0.5% | +0.3% | -6.6% | +4.9% | +4.9% | -0.5% | — |
| Oct 31, 2024 | BMO | -0.60 | -0.56 | +6.7% | 4.76 | -0.2% | -0.2% | -1.5% | -3.4% | +4.6% | +12.1% | — |
| Aug 1, 2024 | BMO | -0.53 | -0.56 | -5.7% | 6.88 | -3.2% | +2.3% | -2.3% | +2.0% | -2.7% | +2.5% | — |
| May 8, 2024 | BMO | -0.52 | -0.55 | -5.8% | 8.50 | +0.7% | +0.5% | -8.0% | +3.3% | +0.6% | +1.3% | — |
| Feb 29, 2024 | BMO | -0.37 | -0.53 | -43.2% | 10.27 | -0.6% | +11.8% | +0.2% | -5.5% | +0.4% | +3.4% | — |
| Nov 2, 2023 | BMO | -0.50 | -0.67 | -34.0% | 5.95 | +1.0% | +7.7% | -3.4% | -2.3% | -7.9% | -3.1% | — |
| Aug 3, 2023 | BMO | -0.69 | -0.62 | +10.1% | 8.98 | +1.8% | -5.0% | -7.7% | +3.7% | -0.4% | +0.7% | — |
| May 11, 2023 | AMC | -0.73 | -0.57 | +21.9% | 8.52 | -0.1% | -3.3% | +3.6% | -1.8% | +1.3% | -0.9% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 22 | Wolfe Research | Initiates | Outperform | — | $11.59 | $12.04 | +3.9% | +1.9% | +3.6% | -3.1% | +0.6% | +9.6% |
| May 4 | Jefferies | Initiates | Buy | $18 | $9.01 | $9.17 | +1.8% | +5.7% | -2.1% | +4.7% | -3.8% | +5.5% |
| Apr 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.89 | $8.75 | -1.6% | -5.1% | -0.7% | +8.1% | -0.6% | +5.7% |
| Apr 24 | B. Riley Securities | Initiates | Buy | $17 | $9.15 | $9.72 | +6.2% | +4.7% | -7.2% | -5.1% | -0.7% | +8.1% |
| Apr 20 | BTIG | Maintains | Buy → Buy | — | $6.66 | $8.65 | +29.9% | +42.0% | -2.2% | -5.4% | +4.6% | +4.7% |
| Mar 26 | Canaccord Genuity | Maintains | Buy → Buy | — | $5.62 | $5.50 | -2.1% | +0.4% | -4.8% | -2.4% | +5.5% | +1.6% |
| Mar 25 | Morgan Stanley | Maintains | Overweight → Overweight | — | $5.22 | $5.31 | +1.7% | +7.7% | +0.4% | -4.8% | -2.4% | +5.5% |
| Mar 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.90 | $6.73 | -2.5% | +1.7% | -1.0% | +1.4% | -3.8% | -2.9% |
| Feb 18 | RBC Capital | Maintains | Outperform → Outperform | — | $7.63 | $8.26 | +8.3% | +10.7% | -2.2% | -2.5% | -2.5% | +1.8% |
| Feb 18 | Canaccord Genuity | Maintains | Buy → Buy | — | $7.63 | $8.26 | +8.3% | +10.7% | -2.2% | -2.5% | -2.5% | +1.8% |
| Feb 18 | Morgan Stanley | Maintains | Overweight → Overweight | — | $7.63 | $8.26 | +8.3% | +10.7% | -2.2% | -2.5% | -2.5% | +1.8% |
| Jan 23 | RBC Capital | Maintains | Outperform → Outperform | — | $7.13 | $7.26 | +1.8% | +0.6% | -3.8% | +1.3% | -4.0% | +1.2% |
| Nov 5 | Morgan Stanley | Maintains | Overweight → Overweight | — | $6.63 | $6.54 | -1.4% | -17.2% | +1.8% | -2.5% | +5.3% | -0.7% |
| Oct 13 | BTIG | Maintains | Buy → Buy | — | $6.22 | $6.26 | +0.6% | +1.1% | +8.7% | -0.1% | -6.1% | +1.7% |
| Aug 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.34 | $4.36 | +0.5% | +6.0% | -2.6% | -2.7% | -1.1% | +1.9% |
| Aug 1 | Canaccord Genuity | Maintains | Buy → Buy | — | $4.35 | $4.27 | -1.8% | -0.2% | +6.0% | -2.6% | -2.7% | -1.1% |
| Jul 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.71 | $3.71 | +0.0% | -4.0% | +10.4% | -1.3% | +10.8% | +3.7% |
| Jul 15 | HC Wainwright& Co. | Maintains | Buy → Buy | — | $3.71 | $3.71 | +0.0% | -4.0% | +10.4% | -1.3% | +10.8% | +3.7% |
| Jun 23 | Evercore ISI | Downgrade | Outperform → In Line | — | $4.63 | $3.08 | -33.5% | -49.2% | +7.7% | +9.1% | -3.6% | +4.1% |
| May 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.79 | $4.00 | +5.5% | +3.2% | -0.3% | -1.0% | +2.3% | +0.8% |
| Mar 28 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $3.09 | $3.06 | -1.0% | -4.9% | -2.7% | -2.4% | +10.8% | -8.4% |
| Mar 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.67 | $3.60 | -1.9% | +4.9% | +4.9% | -0.5% | -7.0% | -5.3% |
| Feb 28 | Canaccord Genuity | Maintains | Buy → Buy | — | $3.92 | $3.90 | -0.5% | +0.3% | -6.6% | +4.9% | +4.9% | -0.5% |
| Feb 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.25 | $4.34 | +2.1% | +4.0% | +3.4% | -3.1% | +1.6% | +0.9% |
| Jan 15 | RBC Capital | Maintains | Outperform → Outperform | — | $3.36 | $3.40 | +1.2% | +2.7% | -1.2% | +2.3% | +4.3% | +2.5% |
| Nov 1 | RBC Capital | Maintains | Outperform → Outperform | — | $4.76 | $4.75 | -0.2% | -0.2% | -1.5% | -3.4% | +4.6% | +12.1% |
| Nov 1 | Maxim Group | Maintains | Buy → Buy | — | $4.76 | $4.75 | -0.2% | -0.2% | -1.5% | -3.4% | +4.6% | +12.1% |
| Nov 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.76 | $4.75 | -0.2% | -0.2% | -1.5% | -3.4% | +4.6% | +12.1% |
| Sep 10 | RBC Capital | Maintains | Outperform → Outperform | — | $6.75 | $6.74 | -0.1% | +0.9% | +0.6% | -1.0% | +6.9% | -0.7% |
| Aug 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.95 | $7.18 | +3.3% | +3.5% | +11.3% | +0.0% | -1.2% | -3.3% |
| Aug 2 | Canaccord Genuity | Maintains | Buy → Buy | — | $6.88 | $6.66 | -3.2% | +2.3% | -2.3% | +2.0% | -2.7% | +2.5% |
| Jul 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.61 | $7.65 | +0.5% | +0.3% | -9.8% | +2.3% | -2.3% | +2.0% |
| May 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.86 | $8.04 | +2.3% | +3.3% | +0.6% | +1.3% | -3.5% | -1.9% |
| Mar 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.27 | $10.21 | -0.6% | +11.8% | +0.2% | -5.5% | +0.4% | +3.4% |
| Aug 22 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $9.16 | $9.15 | -0.2% | +2.9% | -2.8% | -3.5% | +1.4% | +1.6% |
| Aug 22 | Canaccord Genuity | Maintains | Buy → Buy | — | $9.16 | $9.15 | -0.2% | +2.9% | -2.8% | -3.5% | +1.4% | +1.6% |
| Aug 17 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $9.05 | $8.95 | -1.1% | -7.2% | -1.9% | +11.2% | +2.9% | -2.8% |
| Jul 13 | EF Hutton | Maintains | Buy → Buy | — | $9.06 | $9.07 | +0.1% | +5.2% | -4.7% | +0.5% | +6.5% | -6.5% |
| Jul 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.90 | $9.06 | +1.8% | +4.9% | +5.8% | +7.9% | -5.7% | -9.9% |
| Jun 21 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $8.30 | $8.26 | -0.5% | +0.5% | -4.2% | -1.6% | -3.6% | +3.7% |
| Jun 20 | EF Hutton | Maintains | Buy → Buy | — | $7.69 | $8.07 | +4.9% | +7.9% | +0.5% | -4.2% | -1.6% | -3.6% |
| Jun 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.48 | $7.48 | +0.0% | +9.8% | +0.6% | -2.4% | -2.7% | +2.4% |
| May 30 | EF Hutton | Maintains | Buy → Buy | — | $7.65 | $7.65 | +0.0% | -2.5% | -1.6% | +3.4% | +3.8% | -5.1% |
| May 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.24 | $8.30 | +0.7% | +3.6% | -1.8% | +1.3% | -0.9% | -4.3% |
| May 11 | EF Hutton | Maintains | Buy → Buy | — | $8.59 | $8.68 | +1.0% | -0.8% | -3.3% | +3.6% | -1.8% | +1.3% |
| Apr 12 | EF Hutton | Maintains | Buy → Buy | — | $10.34 | $10.61 | +2.6% | -2.7% | -1.1% | -0.1% | +1.8% | -2.0% |
| Mar 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.97 | $8.00 | +0.4% | -2.8% | +4.4% | +4.2% | -2.5% | +5.6% |
| Mar 1 | Citigroup | Maintains | Buy → Buy | — | $8.25 | $8.32 | +0.8% | -1.5% | +5.2% | -0.7% | -3.2% | -1.7% |
| Feb 28 | EF Hutton | Maintains | Buy → Buy | — | $8.42 | $8.21 | -2.5% | -2.0% | -1.5% | +5.2% | -0.7% | -3.2% |
| Dec 16 | EF Hutton | Maintains | Buy → Buy | — | $9.75 | $10.13 | +3.9% | +0.9% | -5.6% | -1.0% | -1.0% | -2.0% |
No insider trades available.
8-K
COMPASS Pathways plc -- 8-K Filing
May 28
8-K · 2.02
!! High
COMPASS Pathways plc -- 8-K 2.02: Earnings Results
May 13
8-K · 7.01
! Medium
COMPASS Pathways Plc American Depository Shares -- 8-K 7.01: Regulation FD Disclosure
COMPASS Pathways priced a public offering on February 18, 2026, though specific terms remain unavailable in this filing disclosure.
Feb 19
8-K · 8.01
!! High
COMPASS Pathways Plc American Depository Shares -- 8-K 8.01: Material Event / Announcement
COMPASS Pathways achieved the primary endpoint in its Phase 3 COMP006 trial for COMP360 psilocybin treating treatment-resistant depression, meeting efficacy criteria for potential regulatory approval.
Feb 17
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Rtw Investments, Lp | 10,632,390 | $59M | Added | Mar 2026 |
| 2 | Marshall Wace, Llp | 4,038,335 | $22M | New | Mar 2026 |
| 3 | Bit Capital Gmbh | 3,491,234 | $19M | Added | Mar 2026 |
| 4 | Ark Investment Management Llc | 3,301,050 | $18M | Added | Mar 2026 |
| 5 | Toronto Dominion Bank | 2,529,013 | $17M | Added | Dec 2025 |
| 6 | Millennium Management | 3,138,522 | $17M | Added | Mar 2026 |
| 7 | Morgan Stanley | 2,275,040 | $16M | Added | Dec 2025 |
| 8 | Two Sigma Investments, Lp | 2,583,499 | $14M | Added | Mar 2026 |
| 9 | Ubs Group Ag | 1,855,070 | $10M | Reduced | Mar 2026 |
| 10 | Heights Capital Management, Inc | 1,492,415 | $8M | New | Mar 2026 |
| 11 | Aisling Capital Management Lp | 1,432,336 | $8M | Added | Mar 2026 |
| 12 | Susquehanna International Group, Llp | 1,122,588 | $6M | Added | Mar 2026 |
| 13 | Ally Bridge Group (Ny) Llc | 1,045,000 | $6M | New | Mar 2026 |
| 14 | Alyeska Investment Group, L.p. | 1,000,000 | $6M | New | Mar 2026 |
| 15 | Qube Research & Technologies Ltd | 948,554 | $5M | New | Mar 2026 |
| 16 | Renaissance Technologies Llc | 865,354 | $5M | Reduced | Mar 2026 |
| 17 | Kalehua Capital Management Llc | 819,692 | $5M | — | Mar 2026 |
| 18 | Propel Bio Management, Llc | 742,049 | $4M | Reduced | Mar 2026 |
| 19 | Walleye Capital Llc | 724,304 | $4M | Added | Mar 2026 |
| 20 | Jane Street Group, Llc | 336,728 | $2M | Added | Dec 2025 |
Mutual Funds / ETFs (N-PORT) — Top 12
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | ARK Genomic Revolution ETF | 2,145,054 | $14M | Jan 2026 |
| 2 | PGIM Jennison Health Sciences Fund | 610,510 | $4M | Feb 2026 |
| 3 | iShares Biotechnology ETF | 612,150 | $3M | Mar 2026 |
| 4 | Columbia Small Cap Value Discovery Fund | 406,210 | $3M | Jan 2026 |
| 5 | Royce Smaller-Companies Growth Fund | 249,000 | $1M | Mar 2026 |
| 6 | AdvisorShares Psychedelics ETF | 246,739 | $1M | Mar 2026 |
| 7 | ROYCE SMALL-CAP TRUST, INC. | 133,000 | $735K | Mar 2026 |
| 8 | Fidelity Nasdaq Composite Index Fund | 62,962 | $434K | Feb 2026 |
| 9 | Saba Capital Income & Opportunities Fund | 61,188 | $409K | Jan 2026 |
| 10 | Virtus LifeSci Biotech Clinical Trials ETF | 41,800 | $280K | Jan 2026 |
| 11 | Invesco Nasdaq Biotechnology ETF | 5,259 | $36K | Feb 2026 |
| 12 | ProShares Ultra Nasdaq Biotechnology | 4,351 | $30K | Feb 2026 |
Valuation
Market Cap
$1.17B
Enterprise Value
$1.02B
P/E (TTM)
—
Forward P/E
—
PEG Ratio
-0.07x
P/B
—
P/S
—
P/FCF
-7.45x
EV/EBITDA
—
Shares Out
93.5M
Financials (TTM)
Revenue
$0
Net Income
-$178.9M
EBITDA
-$176.6M
Free Cash Flow
-$157.2M
Op Cash Flow
-$157.2M
EPS Basic
$-3.08
EPS Diluted
$-3.15
EPS Forward
$-1.80
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$210.3M
Total Liab.
$263.2M
Total Equity
-$52.8M
Cash
$149.6M
LT Debt
$1.3M
Book Value/Sh
$-0.57
Debt/Equity
-0.40x
Current Ratio
0.77
Quick Ratio
0.77
Returns & Growth
ROE
544.7%
ROA
-136.8%
ROIC
996.5%
Rev Growth YoY
+0.0%
EPS Growth YoY
-33.9%
Price Returns
2W
+23.0%
1M
+44.2%
3M
+89.3%
6M
+135.3%
12M
+213.9%
Technicals
52W High
$14.19
52W Low
$2.35
50d MA
$10.11
200d MA
$7.19
RSI (14)
46.60
ATR (14)
$0.98
Beta
2.02
Avg Volume
3.9M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$17.83
High
$22.00
Low
$15.00
Median
$17.50
Data updated apr 26, 2026 10:12am
· Source: financialmodelingprep.com